Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelon plus gemcitabine for first-line unresectable advanced pancreatic cancer
ChiCTR2300069173Phase 2Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Sep 2022
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone and gemcitabine in pancreatic cancer (PC), sponsored by Shanghai General Hospital. Primary endpoints: overall survival, progression-free survival and 1 more. Started Sep 2022; status: recruiting.
02
Drugs
utidelonegemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2300069173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069173.